

-22-

Claims:

1. A method for treating allergic responses comprising contacting inflamed tissue with a preparation comprising at least one member selected from the group  
5 consisting of IL-1 receptors, TNF receptors, and receptor analogues thereof which are capable of binding either IL-1 or TNF.

2. The method of claim 1, wherein a substantial  
10 portion of the receptors or analogues contained in the preparation are soluble.

3. The method of claim 1, wherein said preparation comprises a mixture of IL-1 receptors and TNF receptors.

4. The method of claim 3, wherein at least a  
15 portion of said TNF receptors are covalently bound to said IL-1 receptors.

5. The method of claim 3, wherein at least a portion of said receptor analogues are hybrid fusion molecules comprising a TNF receptor moiety and an IL-1 receptor moiety.

20 6. The method of claim 1, wherein the preparation further comprises a therapeutically effective amount of at least one corticosteroid.

7. The method of claim 5, wherein at least a  
25 portion of said corticosteroids are covalently bound to said IL-1 receptors.

8. The method of claim 1, wherein the tissue to be treated is selected from the group consisting of nasal tissue, ocular tissue, lung tissue, and skin.

-23-

9. A method for testing pharmaceuticals for anti-allergic properties, comprising:

- a) providing a test solution comprising at least one challenging allergen;
- 5 b) providing a pharmaceutical to be tested;
- c) adding said pharmaceutical to said test solution to make a test mixture;
- d) injecting one or more individuals interdermally with said test mixture; and
- 10 e) examining the injection site at intervals after said injecting to determine the extent of an allergic reaction.

10. The method of claim 9, wherein said individuals have previously displayed a dual allergic response (early and late) to intradermal challenge with said allergen.

11. The method of claim 9, wherein said examining step comprises measuring the area of the wheal reaction on the skin of the individuals.

12. A therapeutic composition for treating allergic responses comprising at least one member selected from the group consisting of IL-1 receptors, TNF receptors, and receptor analogues thereof which are capable of binding either IL-1 or TNF, together with a pharmaceutically acceptable carrier adapted for topical or parenteral application to a host in need of such treatment.

13. The therapeutic composition of claim 12, wherein a substantial portion of the receptors or analogues contained in the preparation are soluble.

-24-

14. The therapeutic composition of claim 12,  
wherein said preparation comprises a mixture of IL-1  
receptors and TNF receptors.

5 15. The therapeutic composition of claim 14,  
wherein at least a portion of said TNF receptors are  
covalently bound to said IL-1 receptors.

10 16. The therapeutic composition of claim 14,  
wherein at least a portion of said receptor analogues are  
hybrid fusion molecules comprising a TNF receptor moiety  
and an IL-1 receptor moiety.

17. The therapeutic composition of claim 12,  
wherein the preparation further comprises a  
therapeutically effective amount of at least one  
corticosteroid.

15 18. The therapeutic composition of claim 17,  
wherein at least a portion of said corticosteroids are  
covalently bound to said IL-1 receptors.